Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial

Trial Profile

Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2013

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2013 New trial record
    • 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top